Adakveo is an FDA-approved medication used in adults and in children aged 16 years and older with sickle cell disease to prevent vaso-occlusive crisis (VOC).
It contains an active ingredient called crizanlizumab-tmca. Other inactive ingredients include citric acid, polysorbate 80, sodium citrate, and water for injection.
- Generic Name: crizanlizumab-tmca
- Dosage Form: Injection, for intravenous use
- Company: Novartis Pharmaceuticals Corporation
Uses of Adakveo
It is used to treat pain crises in sickle cell disease in adults and children aged 16 years and above. It helps reduce how often such episodes occur.
How To Take Adakveo
Adakveo will be infused into your vein through an intravenous (IV) line over the course of 30 minutes by your healthcare practitioner. The first infusion will be given to you, followed by a second injection two weeks later. Following that, you’ll get an infusion every four weeks.
Other treatments may be prescribed by your healthcare practitioner while you are undergoing treatment. Do not stop receiving this medicine unless your healthcare provider tells you to.
If you are unable to keep an infusion appointment, contact your healthcare practitioner as soon as possible to reschedule.
Side Effects of Adakveo
The following side effects can be associated with taking Actos. They include mild and severe side effects.
Consult your doctor or pharmacist for further information on Actos’s potential adverse effects. They can provide you with advice on how to deal with any unpleasant side effects.
Mild side effects include:
Severe side effects include:
- allergic reaction
- infusion reactions
Within 24 hours after getting an Adakveo infusion, infusion responses can occur. If you have any of the following signs and symptoms of an infusion response, contact your healthcare provider straight away:
- shortness of breath or wheezing
- chills or shivering